Surgical robotics is, at present, one of the most dynamically developing areas of biomedical engineering that has been proven to increase the stability and robustness of surgery. Robotics can integrate, assist, control and extend the human capabilities, correcting for manual errors, or record the spatial points-of-interest and motions. This is of importance as an adjunct to many laparoscopic subspecialty procedures, from cardiac to pelvic surgery. Evidence-based medicine is now demonstrating that robotized equipment can greatly add to the preoperative simulation, the ergonomics of the procedure, the preoperative simulation and the risk-free training of the surgeon with precision surgery and less trauma to the patient. This article discusses the robots that are clinically available at present and their importance to the surgeon and patient.

Subspecialty

Surgical robot

10.1586/erd.10.65

Cite

Citations (5)

p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation

Prostate Cancer and Prostatic Diseases (2005)

Simon Bott Manit Arya Roger Kirby Magali Williamson

Prostatic Diseases

10.1038/sj.pcan.4500822

Cite

Citations (49)

MP01-05 THE RESULTS OF ONE ARM MULTICENTER PROSPECTIVE STUDY ON AN INNOVATIVE MINIMALLY INVASIVE SURGICAL TECHNIQUE FOR LUTS MANAGEMENT: THE SECOND GENERATION TEMPORARY IMPLANTABLE NITINOL DEVICE (I-TIND) MEDITATE®

The Journal of Urology (2019)

F. Porpiglia Cristian Fiori Daniele Amparore G. Volpi Gregor Kadner

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology I (MP01)1 Apr 2019MP01-05 THE RESULTS OF ONE ARM MULTICENTER PROSPECTIVE STUDY ON AN INNOVATIVE MINIMALLY INVASIVE SURGICAL TECHNIQUE FOR LUTS MANAGEMENT: THE SECOND GENERATION TEMPORARY IMPLANTABLE NITINOL DEVICE (I-TIND) MEDITATE® Francesco Porpiglia*, Cristian Fiori, Daniele Amparore, Gabriele Volpi, Gregor Kadner, Arya Manit, Massimo Valerio, Lumen Nicolaas, Brian SH Ho, Sergio Alonso, Claude Schulman, and Neil Barber Francesco Porpiglia*Francesco Porpiglia* More articles by this author , Cristian FioriCristian Fiori More articles by this author , Daniele AmparoreDaniele Amparore More articles by this author , Gabriele VolpiGabriele Volpi More articles by this author , Gregor KadnerGregor Kadner More articles by this author , Arya ManitArya Manit More articles by this author , Massimo ValerioMassimo Valerio More articles by this author , Lumen NicolaasLumen Nicolaas More articles by this author , Brian SH HoBrian SH Ho More articles by this author , Sergio AlonsoSergio Alonso More articles by this author , Claude SchulmanClaude Schulman More articles by this author , and Neil BarberNeil Barber More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000554869.68263.6dAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: A new, minimally invasive, surgical technique to treat benign prostatic hyperplasia (BPH) symptoms is represented by the Temporary Implantable Nitinol Device (TIND-Meditate). We present the results of a one-arm, multi-center, international prospective study to define the efficacy of second generation of MediTate i-TIND in subjects with BPH. METHODS: The i-TIND is composed of three nitinol elongated struts and an anchoring leaflet. It is preloaded by crimping it into the delivery system. When positioned, the struts of expand and determine a radial force with ischemic necrosis and incision of bladder neck and prostatic urethra. The inclusion criteria were: IPSS > 10; peak urinary flow (Qmax) < 12 mL/sec and prostate volume < 75 cc. All patients stopped alpha-blockers and 5alpha-reductase inhibitors before the implantation. The procedure was performed using a rigid 17F cystoscope, under light sedation. 5 days after the implantation the device was removed, without anesthesia. We evaluated demographic, perioperative, functional results and quality of life (QoL) questionnaire. We reported the results at 3, 6 and 12 months. RESULTS: The mean (SD) patient age was 65 (8.9) years, the mean (SD) prostate volume was 40.5 (12.25) mL, mean (SD) Qmax was 7.3 (±2.6 ml/sec), mean (SD) IPSS score was 22.5 (±5.6) and median (SD) IPSS QoL was 4 (2:5). No intraoperative complications were recorded. The devices were retrieved 5.9±1.1 days following implantation. No >grade 2 complications were recorded. Mean Qmax at 1 month follow-up stood at 11.2±5.7 mL/sec and continued to improve thereafter, reaching 14.9±8.1 mL/sec at the 12 month follow-up visit (+ 100%). IPSS urinary symptom scores was 11.7± 8.0 after 1 month and further improved to 8.8±6.4 at the 12 month follow-up (-60%). Mean QoL IPSS score drop reached 1.6±1.3 by the end of the study. During the 12 month period, 2 patients (2.4%) required medications for BPH, 2 patients (2.4%) required TURP. As compared to baseline, none of the 61 sexually active patients who completed the 1 year follow up period reported sexual or ejaculatory dysfunction. CONCLUSIONS: More studies are necessary to define the durability of the results but second generation i-TIND implantation is a safe and effective minimally-invasive technique for the treatment of BPH related symptoms until one year follow up. Source of Funding: none Orbassano, Italy; Frauenfeld, Switzerland; London, United Kingdom; Lausanne, Switzerland; Gent, Belgium; Hong Kong, Hong Kong; Madrid, Spain; Brussels, Belgium; London, United Kingdom© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e2-e2 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Francesco Porpiglia* More articles by this author Cristian Fiori More articles by this author Daniele Amparore More articles by this author Gabriele Volpi More articles by this author Gregor Kadner More articles by this author Arya Manit More articles by this author Massimo Valerio More articles by this author Lumen Nicolaas More articles by this author Brian SH Ho More articles by this author Sergio Alonso More articles by this author Claude Schulman More articles by this author Neil Barber More articles by this author Expand All Advertisement PDF downloadLoading ...

10.1097/01.ju.0000554869.68263.6d

Cite

Citations (0)

166 DR. JACK LAPIDES: PIONEER OF CLEAN INTERMITTENT SELF CATHETERISATION

European Urology Supplements (2009)

Iqbal Shergill Anit Kumar Goyal Philippe Grange Manit Arya J.M. Barua

10.1016/s1569-9056(09)60171-8

Cite

Citations (2)

CURRENT TRENDS IN BLADDER CANCER IN ENGLAND AND WALES

The Journal of Urology (2004)

Dickon Hayne Manit Arya M J Quinn P. Babb Christopher Beacock

No AccessJournal of UrologyAdult Urology: Outcomes/Epidemiology/Socioeconomics1 Sep 2004CURRENT TRENDS IN BLADDER CANCER IN ENGLAND AND WALES D. HAYNE, M. ARYA, M.J. QUINN, P.J. BABB, C.J.M. BEACOCK, and H.R.H. PATEL D. HAYNED. HAYNE , M. ARYAM. ARYA , M.J. QUINNM.J. QUINN , P.J. BABBP.J. BABB , C.J.M. BEACOCKC.J.M. BEACOCK , and H.R.H. PATELH.R.H. PATEL View All Author Informationhttps://doi.org/10.1097/01.ju.0000136376.11896.62AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We examined trends in bladder cancer (BC) incidence, mortality and survival in England and Wales during a 30-year period. Materials and Methods: Age standardized incidence and mortality rates for BC, cohort incidence ratios, and 1 and 5-year relative survival from BC were calculated, and current trends were assessed. Results: Between 1971 and 1998 the total number of cases of BC increased by 57% from around 7,200 to almost 11,400. Between 1971 and 1998 directly age standardized incidence increased by 16% in males and 37% in females. Directly age standardized mortality decreased by 26% in males and showed little change in females during the same period. Five-year relative survival improved by around 15% points in the 1970s and early 1980s. However, there was less improvement in survival thereafter in that 5-year relative survival for patients diagnosed in 1993 to 1995 was 67% in men and 58% in women. Conclusions: With an almost 60% increased incidence during the last 3 decades, BC incidence remains much higher in men but has increased more rapidly in women. There have been steady decreases in mortality rates, more marked in men than in women. Unusually, women have a significantly lower survival rate than men. Reasons for these patterns and trends are unclear. The trends in bladder cancer incidence by birth cohort suggest that the relationship with smoking may not be that strong and that other factors may be involved. Further research should focus on reasons for the recent increase in bladder cancer incidence in younger female birth cohorts. References 1 : Trends in the incidence of bladder cancer in Nova Scotia: a twenty-year perspective. Can J Urol2003; 10: 1880. Google Scholar 2 : Incidence of bladder cancer in France: trends from 1980 to 2000. Prog Urol2003; 13: 602. Google Scholar 3 : Trends in urinary bladder cancer incidence in Sweden 1960–93 with special reference to histopathology, time period, birth cohort, and smoking. Cancer Causes Control1997; 8: 560. Google Scholar 4 : Cancer Trends in England and Wales 1950–1999. Studies on Medical and Population Subjects No. 66. London: The Stationery Office2001. Google Scholar 5 Cancer Statistics-Registrations, England, 1998. Series MB1 No. 29. London: Office for National Statistics2002. Google Scholar 6 : Mortality trends by cause of death in England and Wales 1980–94: the impact of introducing automated cause coding and related changes in 1993. Popul Trends1996; 86: 29. Google Scholar 7 Mortality Statistics-Cause. Series DH2. London: Office for Population Censuses and Surveys1992. Google Scholar 8 : Report: cancer survival in England and Wales, 1991–1998. Health Stat Q2000; 6: 54. Google Scholar 9 : Report: cancer survival in England and Wales, 1991–1998. Health Stat Q2000; 6: 71. Google Scholar 10 Office for National Statistics, Cancer survival: Five year relative survival rates in England by HA up to 2000—four further cancer sites. www.statistics.gov.uk. Accessed January 2002 Google Scholar 11 : Relative survival and the estimation of net survival: elements for further discussion. Stat Med1990; 9: 529. Google Scholar 12 : Cancer survival trends in England and Wales, 1971–1995: deprivation and NHS region. Studies in Medical and Population Subjects. London: International Agency for Research on Cancer1999. No. 61. Google Scholar 13 : Bladder cancer: race differences in extent of disease at diagnosis. Cancer2000; 89: 1349. Google Scholar 14 : Trends in Cancer Incidence and Mortality. Lyon: International Agency for Research on Cancer1993. No. 121. Google Scholar 15 : Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer2000; 86: 289. Google Scholar 16 : The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control2001; 12: 411. Google Scholar 17 : Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst2001; 93: 538. Google Scholar 18 : Bladder cancer, parity, and age at first birth. Cancer Causes Control1992; 3: 57. Google Scholar 19 : Cancer Incidence and Mortality in England and Wales: Trends and Risk Factors. London: Oxford University Press2001: 148. Google Scholar 20 : Bladder cancer mortality in the United States, 1951–1989: increased environmental carcinogenesis in men. Regul Toxicol Pharmacol1994; 20: 187. Google Scholar 21 : Fluid intake and the risk of bladder cancer in men. N Engl J Med1999; 340: 1390. Google Scholar From the Department of Urology, Royal Shrewsbury Hospital, Shrewsbury (DH, CJMB), National Cancer Intelligence Centre, Office for National Statistics (MJQ, PJB), Institute of Urology and Nephrology, University College London (MA, HRHP), London, and Department of Human Biomonitoring and Carcinogen Activation, The Institute of Cancer Research, Sutton, Surrey, (HRHP), United Kingdom© 2004 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 172Issue 3September 2004Page: 1051-1055 Advertisement Copyright & Permissions© 2004 by American Urological Association, Inc.Keywordsmortalityepidemiologysmokingincidencebladder neoplasmsMetricsAuthor Information D. HAYNE More articles by this author M. ARYA More articles by this author M.J. QUINN More articles by this author P.J. BABB More articles by this author C.J.M. BEACOCK More articles by this author H.R.H. PATEL More articles by this author Expand All Advertisement PDF downloadLoading ...

10.1097/01.ju.0000136376.11896.62

Cite

Citations (26)